The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
AACR-Ocular Melanoma Foundation Fellowship
The AACR-Ocular Melanoma Foundation Fellowship, in honor of Robert C. Allen, MD, represents a joint effort to encourage and support a postdoctoral or clinical research fellow to conduct ocular/uveal melanoma research and to establish a successful career path in ophthalmology, ocular oncology, uveal melanoma biology, or a similar field. The research proposed for funding must be translational or clinical in nature and must have direct, primary applicability and relevance to ocular/uveal melanoma.
This fellowship provides a one-year grant of $50,000 to support the salary and benefit of the fellow while working on mentored ocular/uveal melanoma research. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.
Deadline: Jan. 16, 2020
Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.
At the start of the grant term on July 1, 2020, applicants must hold a mentored research position with the title of postdoctoral fellow, clinical research fellow, or the equivalent and have completed their most recent doctoral degree within the past five years. Applicants must work under the auspices of a mentor at an academic, medical, or research institution anywhere in the world.
Investigators may submit only one application for the AACR-Ocular Melanoma Foundation Fellowship, in honor of Robert C. Allen, MD, but may concurrently apply for other AACR grants. However, applicants are expected to accept the first grant they are awarded. Individuals may accept and hold only one AACR grant at a time.